In the final parsimonious multivariable model, use of COX-2 inhibitors for ≥6 months at the time of index cancer diagnosis was associated with significantly reduced odds of EOGC development (OR 0.39, 95% CI 0.16-0.94). The gene discussed is PTGS2; the disease is cancer.